Thus, FGF19 and NGM282 appear to selectively modulate LXR signaling, upregulating canonical LXR target genes (Abcg5, Abcg8, Scarb1, Srebf1, Fasn, Scd1, Srebf2, and Scap) without inducing hepatic steatosis. The gene discussed is SCARB1; the disease is fatty liver disease.